<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211922</url>
  </required_header>
  <id_info>
    <org_study_id>ZGALK002</org_study_id>
    <nct_id>NCT04211922</nct_id>
  </id_info>
  <brief_title>Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib</brief_title>
  <official_title>A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of the study is to evaluate safety and efficacy of Alkotinib capsule in
      patients with ALK-positive non-small cell lung cancer previously treated with
      crizotinib.While exploring the relationship between biomarkers and drug efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called alkotinib. Alkotinib has been demonstrated to
      benefit people with ALK+ NSCLC.

      The study is a non-control study.

      The study will enroll approximately 104 participants. All participants will take alkotinib
      300mg throughout the study.

      This multi-center trial will be conducted in China. The overall time to participate in this
      study is 3 years. Participants will make multiple visits to the site, and 28 days after last
      dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) based on independent radiology review</measure>
    <time_frame>24 months</time_frame>
    <description>ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) as assessed by independent radiology review and investigator</measure>
    <time_frame>36 months</time_frame>
    <description>PFS, defined as time from first dose of Alkotinib to progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>OS, defined as time from first dose of Alkotinib to death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>ALK-positive Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Alkotinib 400mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg orally once daily. Take Alkotinib at least 1 hour before or at least 2 hours after a meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alkotinib Capsules</intervention_name>
    <description>Alkotinib 400mg QD</description>
    <arm_group_label>Alkotinib 400mg QD</arm_group_label>
    <other_name>ZG0418</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Evidence of positive ALK.

          -  Patients must have demonstrated progression during or after crizotinib treatment.

          -  Age 18 years or older at the time of informed consent.

          -  Eastern cooperative oncology group performance status (ECOG PS) of 0-2

          -  At least one measurable lension by response evaluation criteria in solid tumors
             (RECIST) version 1.1 (v1.1).

          -  Willingness and ability to comply with the trial and follow-up procedures.

        Exclusion Criteria:

          -  chemotherapy, radiation therapy, immunotherapy within 4 weeks.

          -  Presence of active gastrointestinal (GI) disease or other condition that will
             interfere significantly with the absorption, distribution, metabolism, or excretion of
             study medications.

          -  Uncontrolled mass of pleural effusion, pericardial effusion, and peritoneal effusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caicun Zhou, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caicun Zhou, Dr.</last_name>
    <phone>021-65115006</phone>
    <phone_ext>1027</phone_ext>
    <email>caicunzhoudr@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bangyu Zhang</last_name>
    <phone>021-65115006</phone>
    <phone_ext>1027</phone_ext>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caicun Zhou, Doctor</last_name>
      <phone>021-65115006</phone>
      <email>caicunzhoudr@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

